The future of Europe as a pharmaceutical manufacturing location is a topic of growing interest and debate. With increasing global competition, regulatory challenges, and the impact of events such as the Brexit etc., there are uncertainties surrounding Europe’s position in the pharmaceutical industry. However, Europe’s strong research and development capabilities, skilled workforce, robust infrastructure, and commitment to quality standards provide a solid foundation for continued growth and innovation in pharmaceutical manufacturing. Strategic investments can secure Europe`s future as a leading pharmaceutical manufacturing hub but this is increasingly threatened by Asia – mainly China and India.

In this session we will discuss…

• What is the current competence profile of manufacturers in Europe?
• How are the China and India locations currently developing?
• Why is the Far East so attractive as a pharmaceutical manufacturing location?
• What active ingredients do we still produce economically in Europe? Which active ingredients come from where? What is the danger?
• What is the vertical range of manufacture in Asia vs. Europe and what does that mean?